Earnings · China A-shares
Wuhan Hiteck Biological Pharma Co., Ltd. Class A (300683) earnings
Wuhan Hiteck Biological Pharma Co., Ltd. Class A published its Q3 report on 2026-10-22: net profit +24.56% year on year, +30.15% excluding one-off items. Wave Radar's earnings-quality score is 59 of 100 (Questionable). The stock moved -5.39% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-22
- Period end
- 2026-09-30
- Net profit YoY
- +24.56%
- Excl. one-offs YoY
- +30.15%
- Result
- Bad / loss
- Quality score
- 59
- Quality
- Questionable
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | +2.70% | — |
| 3 days | -5.39% | — |
| 7 days | -4.35% | — |
| 14 days | +0.13% | — |
Report history
Over the last 8 reports, net profit grew year on year in 3 of them. The stock rose in the 3 trading days after 2 of 6 reports (average -3.88%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-23 | -¥119.27M | +24.56% | +30.15% | -25.63% | -0.91 | -5.68% | -5.39% | — | — |
| 2026 interim report | 2026-08-24 | -¥78.71M | -100.89% | -39.65% | -18.01% | -0.60 | -3.71% | -9.97% | -13.33% | -6.42% |
| 2026 Q1 report | 2026-04-24 | -¥23.05M | -65.44% | -39.36% | +1.52% | -0.18 | -1.07% | +9.49% | -22.77% | -23.19% |
| 2025 annual report | 2026-04-24 | -¥231.27M | -233.48% | — | -16.57% | -1.77 | -10.16% | +9.49% | -22.77% | -23.19% |
| 2025 Q3 report | 2025-10-23 | -¥158.09M | -297.78% | — | -6.45% | -1.21 | -6.84% | -5.04% | -13.93% | -13.06% |
| 2025 interim report | 2025-08-26 | -¥39.18M | -72.10% | -22.19% | -3.36% | -0.30 | -1.65% | -15.33% | -45.16% | -46.84% |
| 2025 Q1 report | 2025-04-21 | -¥13.93M | +15.81% | +24.55% | +18.79% | -0.11 | -0.58% | +2.97% | +23.04% | +20.09% |
| 2024 annual report | 2025-04-21 | -¥69.35M | +42.60% | +29.11% | +7.75% | -0.53 | -2.84% | +2.97% | +23.04% | +20.09% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.